Editas Medicine (EDIT) EBITDA (2015 - 2025)
Editas Medicine (EDIT) posted quarterly EBITDA of -$24.5 million for Q3 2025, up 62.62% year-over-year from -$15.1 million in Q3 2024, and up 52.37% quarter-over-quarter from -$51.5 million in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) EBITDA (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported EBITDA for 11 consecutive years, with -$24.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, EBITDA rose 62.62% year-over-year to -$24.5 million; the TTM figure through Sep 2025 stood at -$198.8 million (up 12.99% YoY), while the FY2024 annual figure was -$251.2 million, down 48.45% from the prior year.
- EBITDA rose to -$24.5 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$24.0 million in Q4 2023 and bottomed at -$76.2 million in Q1 2025.
- Historically, EBITDA has averaged -$52.2 million across 5 years, with a median of -$51.5 million in 2025.
- Annual changes were most pronounced in 2021 — EBITDA slumped 536.68% — and 2025, when it soared 62.62%.
- Editas Medicine's EBITDA stood at -$41.6 million in 2021, then tumbled by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then sank by 94.45% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
- Business Quant data shows EDIT's EBITDA at -$24.5 million in Q3 2025, -$51.5 million in Q2 2025, and -$76.2 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -24.55 Mn |
| Jun 30, 2025 | -51.54 Mn |
| Mar 31, 2025 | -76.16 Mn |
| Dec 31, 2024 | -46.59 Mn |
| Sep 30, 2024 | -65.67 Mn |
| Jun 30, 2024 | -71.90 Mn |
| Mar 31, 2024 | -66.99 Mn |
| Dec 31, 2023 | -23.96 Mn |
| Sep 30, 2023 | -50.16 Mn |
| Jun 30, 2023 | -44.09 Mn |
| Mar 31, 2023 | -50.96 Mn |
| Dec 31, 2022 | -63.45 Mn |
| Sep 30, 2022 | -57.52 Mn |
| Jun 30, 2022 | -54.23 Mn |
| Mar 31, 2022 | -50.75 Mn |
| Dec 31, 2021 | -41.61 Mn |
| Sep 30, 2021 | -39.25 Mn |
| Jun 30, 2021 | -55.40 Mn |
| Mar 31, 2021 | -56.88 Mn |
| Dec 31, 2020 | -65.87 Mn |